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Abstract: Metal-based nanoparticles have been extensively investigated for a set of biomedical 
applications. According to the World Health Organization, in addition to their reduced size and 
selectivity for bacteria, metal-based nanoparticles have also proved to be effective against pathogens 
listed as a priority. Metal-based nanoparticles are known to have non-specific bacterial toxicity 
mechanisms (they do not bind to a specific receptor in the bacterial cell) which not only makes the 
development of resistance by bacteria difficult, but also broadens the spectrum of antibacterial 
activity. As a result, a large majority of metal-based nanoparticles efficacy studies performed so far 
have shown promising results in both Gram-positive and Gram-negative bacteria. The aim of this 
review has been a comprehensive discussion of the state of the art on the use of the most relevant 
types of metal nanoparticles employed as antimicrobial agents. A special emphasis to silver 
nanoparticles is given, while others (e.g., gold, zinc oxide, copper, and copper oxide nanoparticles) 
commonly used in antibiotherapy are also reviewed. The novelty of this review relies on the 
comparative discussion of the different types of metal nanoparticles, their production methods, 
physicochemical characterization, and pharmacokinetics together with the toxicological risk 
encountered with the use of different types of nanoparticles as antimicrobial agents. Their added-
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value in the development of alternative, more effective antibiotics against multi-resistant Gram-
negative bacteria has been highlighted. 
Keywords: antibacterial activity; metal-based nanoparticles; AgNPs; CuONPs; AuNPs; ZnONPs 
 
1. Introduction 
Bacteria were the first living organisms found on the Earth and they have become highly 
adaptable over the course of time. During the 20th century, the discovery of antibiotics was considered 
one of the most significant medical achievements of the humankind [1]. It began with the discovery 
of Salvarsan, one of the first medicines capable of curing an infectious disease—syphilis—without 
being toxic to the patients. However, it was not until the accidental discovery of penicillin, in 1928, 
by Alexander Fleming, that research of antibiotics started, reaching its peak between the 1950s and 
1960s, a period that became known as the “golden age” [1]. More than 20 new classes of antibiotics 
were produced between 1930 and 1962, but due to the evolution of new resistant bacteria, discovery 
of new molecules with antibacterial activity has become even more challenging to the pharmaceutical 
industry [2,3]. 
Antibiotic resistance bacteria are one of the main causes of lack of efficacy of antimicrobial 
agents. Bacterial resistance is caused by modifications in the ability of microorganisms to resist 
against antibacterial agents either by inactivating them or by causing a decrease in their therapeutic 
efficacy. Over time, these resistances appear spontaneously in microorganisms due to genetic 
modifications. The inappropriate use and abuse of antibiotics considerably favors such modifications 
[3]. This leads to extended infection periods, increased mortality rates, and further economic burden 
in health systems [4]. Besides the genetic mutations in the microorganism, bacterial resistance can 
result from the exchange of genetic material among bacteria or phages by: (i) DNA transformation, 
which is the uptake and incorporation of a DNA fragment; or by (ii) transduction or transfer of 
bacterial genes through a virus and conjugation, consisting on the transfer of genetic material 
between a donor and a receptor microorganism [3]. Antibiotic resistance has very diverse 
mechanisms such a enzymatic mechanisms using by β-lactamases, acetyltransferases or 
aminoglycoside modifying enzymes [5]. Alteration of membrane permeability preventing the 
penetration of the antimicrobial agent is also a common resistance mechanism, together with changes 
in the antimicrobial target (e.g., penicillin-binding proteins or mutations in DNA gyrase and 
topoisomerase IV) [6]. 
Since the “golden age”, only three new classes of antibiotics active against Gram-positive 
bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), were discovered and approved: 
oxazolidinones (linezolid in 2001 and tedizolid in 2014), daptomycin in 2006 (a cyclic lipopeptide) 
and fidaxomicin in 2011 (a macrocycle drug for C. difficile). However, a high number of analogues of 
existing classes and antibiotic combinations has reached the market [2]. Figure 1 shows the timeline 
of appearance of antibiotic resistance versus antibiotic development, highlighting the rapid resistance 
development by bacteria. 
Despite the trend for the increasing need of new antibiotics, global disincentives to the use of 
antibiotics significantly reduced the sales volume when compared to other drugs (e.g., those used in 
chronic diseases) [7]. In fact, over the recent years, the number of companies involved in the research 
of new antibiotics has decreased from 25 in 1980 to less than a half remaining Glaxo Smith Kline, 
Johnson & Johnson, Merck & Co., and Pfizer, while other large pharmaceutical companies have 
redirected their resources to the development of drugs for chronic diseases and other areas, such as 
cancer, where the market share is higher and drugs can be marketed at higher prices [8]. 
In an attempt to reverse this scenario, international authorities have sought to address multi-
resistant infection management measures and to promote research and development (R&D) of new 
therapeutic entities. In February 2017, the World Health Organization published a Global Priority 
Pathogens List (PPL). Among others, bacterial infections were considered as the greatest concern to 
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public health. For this reason, it is remarkably clear that there is an urgent need for new substances 
with antibacterial properties. The main objective of this guideline has been to drive researchers to 
prioritize the R&D of new antibiotics [9]. This report established Gram-negative bacteria as the most 
critical pathogens for antibiotic R&D, since some strains that cannot be treated with none of the 
antibiotics currently on the market [1]. In March 2018, DRIVE-AB was created. DRIVE-AB project 
consists in 15 public partners and 7 private partners responsible for setting guidelines for the rational 
use of antibiotics, funded by the Innovative Medicines Initiative (IMI). The consortium published a 
report setting out four incentives considered highly effective in stimulating the pipeline of antibiotics. 
Grants (for R&D in academic institutions, companies and others), and the pipeline coordinators 
(governmental or non-profit organizations that track the antibiotic pipeline, identify gaps and 
actively support R&D projects) are intended to stimulate the early stages of developing and support 
research groups during the early stages of development. Once the development phase is completed, 
market entry rewards aim to make the antibiotic market more appealing for investment by giving the 
companies a reward of, e.g., $1 billion per new antibiotic. These incentives have also been set to fill 
the low sales volume of new antibiotics. DRIVE-AB has proposed a long-term supply continuity 
model designed to ensure the continuous supply of essential antibiotics through a series of annual 
fixed payments to the supplier [10]. 
These new incentives stimulated the interest of pharmaceutical companies involved in the 
development of non-traditional drugs, especially nanotechnology industries, which have invested in 
the development of new nanomaterials identified as promising agents against bacteria resistant to 
traditional antibiotics. 
 
Figure 1. Development of antibiotics and appearance of bacterial resistance over time. 
2. Metal Nanoparticles: Overview 
Metal-based nanoparticles are the most popular inorganic nanoparticles and represent a 
promising solution against the resistance to traditional antibiotics. Not only do they use mechanisms 
of action that are completely different from those described for traditional antibiotics, exhibiting 
activity against bacteria that have already developed resistance, but they also target multiple 
biomolecules compromising the development of resistant strains [11]. 
Metal-based nanoparticles may be characterized by numerous techniques. These methods 
provide valuable information about their morphology, physicochemical, and electric properties 
which are crucial for their in vivo activity. The most relevant properties of nanoparticles include 
aspects as their size, shape, roughness, and surface energy [12]. 
2.1. Metal-Based Nanoparticle General Mechanisms  
Bacteria have specific characteristics that explain their behaviour in contact with metal 
nanoparticles. Since the main toxicological effect induced by antimicrobial compounds in bacteria 
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occurs by direct contact with the cell surface, it is important to understand the differences between 
the cell wall of Gram-positive and Gram-negative bacteria [12]. 
Both Gram-positive and Gram-negative bacteria have a negatively charged surface [11]. Gram-
positive bacteria have a thick layer of peptidoglycan formed by linear chains alternating residues of 
N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) linked together by a sequence of 3 to 
5 amino acids that cross-link each other, forming a cohesive mesh. Additionally, negatively charged 
teichoic acids (with high levels of phosphate groups) extend from the cell wall to the surface of most 
Gram-positive bacteria. Gram-negative bacteria, on the other hand, have a slightly more complex 
structure. In addition to the thin layer of peptidoglycan, Gram-negative bacteria have a phospholipid 
outer membrane with partially phosphorylated lipopolysaccharides (LPS) that contribute to increase 
the negative surface charge of their cell envelope [13]. 
Negatively charged bacterial cell walls attract positively charged nanoparticles to their surface 
due to electrostatic interactions. On the other hand, positively charged metal-based nanoparticles 
establish a strong bond with membranes, resulting in disruption of cell walls and, consequently, 
increase their permeability. In addition, nanoparticles can also release metal ions from the 
extracellular space, capable of entering the cell and disrupt biological processes [14]. Inside the cell, 
either metal ions or nanoparticles can induce production of reactive oxygen species (ROS). The 
oxidative stress generated leads to oxidation of glutathione, thus suppressing the antioxidant defence 
mechanism of bacteria against ROS. The metal ions are then free to interact with cellular structures 
(e.g., proteins, membranes, DNA), disrupting cell functions [14]. Metal ions can form strong 
coordination bonds with N, O, or S atoms which are abundant in organic compounds and 
biomolecules. Since the bond between metal ions and biomolecules is generally non-specific, metal-
based nanoparticles generally exhibit a broad spectrum activity [15]. 
2.2. Synthesis of Metal and Metal Oxide Nanoparticles 
Metal-based nanoparticles are not a recent technology. The natural production of metal-based 
nanoparticles by some microorganisms as a mechanism of heavy metals detoxification has been 
described. However, the versatility of this technology has only been described over the last decades, 
with metal-based nanoparticles being widely used in the production of cosmetics and textiles ever 
since [16]. Their versatility has arisen the interest of the scientific community, which began an endless 
search for new compositions, applications, and methods of synthesis. Although research has been 
expanded over the recent years to other less-common metals, the most widely used materials in 
metal-based nanoparticles include silver, gold, copper, iron, and zinc [17–19]. Transition metals are 
expected to be the best candidates for the synthesis of metal-based nanoparticles since these have 
partially filled d-orbitals which make them more redox-active (easier to reduce to zerovalent atoms), 
a feature that facilitates their nanoparticle aggregation [20]. The various synthesis methods developed 
can be classified as physical methods, chemical methods, and more recently developed biological 
methods [18]. 
Physical methods use a top-down approach (Figure 2), starting from bulk metal that undergoes 
fractionation into smaller pieces by mechanical action into successively smaller fragments. Although 
very simplistic, this technique creates nanoparticles with a fairly dispersed size distribution and is 
therefore not the most appropriate in the synthesis of metal-based nanoparticles, in which the size is 
the determining factor for their activity [19]. On the other hand, bottom-up approaches are used in 
chemical methods involving organic solvents and also in biological methods, which are focussed on 
green-synthesis processes using different types of microorganisms. 
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Figure 2. Different methods used for the synthesis of metal-based nanoparticles. 
2.2.1. Thermolysis Methods 
Generally, this technique relies upon the dissociation of organometallic precursors in organic 
solvents at temperatures generally higher than 100 °C under inert atmosphere to avoid surface 
oxidation of the nanoparticles [20]. As a disadvantage of this method, reactions are difficult to apply 
to large-scale synthesis, due to their highly diluted and exothermic conditions. Otherwise, there are 
other methods for the synthesis of nanoparticles, such as controlled thermolysis of silver alkyl 
carboxylates, in order to produce silver nanoparticles (AgNPs) without using organic solvents. As an 
advantage of this method, the controlled thermolysis can be applied to industrial large-scale 
synthesis with very low cost [21]. 
2.2.2. Chemical Reduction Methods 
In these methods, a metal precursor dissolved in a solvent is mixed with both a suitable reducing 
agent and a surfactant in a constantly stirring batch reactor under inert atmosphere. When two or 
more metal cationic species are present in the solvent, a nanosized phase of variable composition is 
formed. This constitutes a promising method to obtain metastable metal nanoparticles. The choice of 
the reducing agent is very wide, but it could be based on the specific redox thermodynamics. 
Moreover, in the majority of the cases, the activity of reducing agents is strongly dependent on the 
pH of the solution [22]. For example, for the preparation of copper nanoparticles (CuNPs), the 
precursor copper acetate is dissolved in stirring deionized water. Hydrazine, the reducing agent, is 
added to the solution and the nanoparticles are formed afterwards [23]. 
2.2.3. Biochemical Methods 
For these methods, plants, algae, yeasts, fungi, bacteria, and even viruses have been recently 
used along with chemical reagents [24]. The growth process is undertaken in intracellular or 
extracellular environment and it relies upon enzymatic or nonenzymatic reduction processes. Gold 
and silver nanoparticles could be synthesized by bacteria or fungi with a multiplicity of shapes 
(cubes, triangles, spheres, plates, or wires) according to the specific host cells and method parameters. 
Despite several patents reporting the use of these methods, biosynthesis process optimization still 
remains an unsolved problem [25].  
2.2.4. Electrochemical Methods 
Electrochemical methods have demonstrated some additional advantages over chemical 
methods in the synthesis of size-selective or shape-controlled highly pure metal nanomaterials. A 
metal sheet is anodically dissolved and the intermediate metal salt formed is reduced at the cathode, 
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giving rise to metallic particles stabilized by ammonium salts [26]. Some authors reported the 
synthesis of bimetallic Cd-Ag nanoalloys by sequential electrodeposition of two different cations on 
a carbon electrode [27]. Similarly, palladium metallic nanostructures were obtained via templated-
assisted electrodeposition from electrolytes containing salts of the relevant cation precursor [28]. 
Other authors reported the synthesis of AuNPs via direct electroreduction of gold ions bulk by 
utilizing polyvinylpyrrolidone (PVP) in enhancing the gold nanoparticle formation and inhibiting 
the metal deposition on the cathode [26]. 
2.2.5. Wave-Assisted Chemical Methods 
Sonochemical methods rely upon the use of a source of ultrasounds inducing cavitation in a 
solution containing a metal precursor mixed with a reducing agent and a surfactant as stabilizer. The 
formation and further implosion of microcavities in the liquid phase produce local spots with 
extremely high temperatures (theoretically higher than 3000 °C) that may trigger chemical reactions 
otherwise unfeasible with traditional techniques [29]. In radiolytic processes, a metal precursor mixed 
with a suitable reducing agent is subject to an electromagnetic or particle irradiation, such as an 
accelerated electron beam [30], gamma-rays [31], X-rays [32], and ultraviolet rays [33]. AgNPs can be 
prepared by ultrasonic wave assisted synthesis, by reducing AgNO3 with strong reducing agent as 
sodium borohydride in the presence of ultrasonic waves. A greyish precipitate is formed, which is 
irradiated ultrasonically and then centrifuged, obtaining the AgNPs [34]. 
Over the last years, micro-wave assisted synthesis has been considered as an eco-friendly and 
fast method. This fact is because the stabilizer and complexing agent can be replaced by less polluting 
materials, such as chitosan and polymers. Moreover, this method is able to carry out chemical 
transformations in minutes. For example, AgNPs can be also prepared by complexing PVP and 
reducing Ag+ ion with N,N-dimethylformamide [35]. 
2.2.6. Cementation Methods 
When a strongly electropositive metal A (sacrificial element) is left in contact with a solution 
containing ions of a less electropositive metal B, the following spontaneous reaction is 
thermodynamically allowed, and metal B separates in elemental form  
A + n/mBm+ = An+ + n/mB (1) 
This reaction, which is commonly used in industry to purify solutions in hydrometallurgy, can 
be used to reduce cations obtaining metal nanoparticles or aggregates with a relatively simple and 
cheap process [36]. The two main disadvantages of this method are the poor control of nanoparticle 
agglomeration owing to a sticking of the cemented metal phase B on the surface element A. However, 
if A contains impurities, they can contaminate B as a consequence of a multicluster surface etching of 
A. These problems can be avoided by damped mechanically with a tailored hydrodynamic control 
[37]. For example, CuNPs can be synthetized with a reduction of copper from a copper nitrate salt in 
the presence of iron, and to prevent the formation of larger sized CuNPs, the sample was 
continuously ultra-sonicated. The obtained nanoparticles sizes were recorded between 90 and 150 
nm [38]. 
2.2.7. Biological Methods 
Biological methods arose from the need to develop new more environmentally friendly 
techniques that exclude the use of organic solvents and toxic chemicals (Table 1). They also proved 
to be safe and economically sustainable alternatives. Critical aspects of the synthesis of metal-based 
nanoparticles, such as size distribution and crystallinity, can be overcome for example by selecting 
the strain, incubation temperature and time, concentration of metal precursor, and optimal pH 
conditions [39].
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Table 1. Examples of green synthesis of alternative metal-based nanoparticles with potential antibacterial activity, with respective minimum inhibitory 
concentration (MIC) and minimum bactericidal concentration (MBC) values 
Specie Microorganism Morphology Synthesis 
Average 
Size 
(nm) 
Activity MIB and MIC Values References 
 AuNPs 
Trichoderma 
hamatum fungus 
spherical, 
pentagonal and 
hexagonal 
extracellular 5–30 P. aeruginosa; Serratia sp.;  B. subtilis; S.aureus  Data not shown [40] 
Alternanthera 
bettzickiana plant extract spherical extracellular 80–120 
S. typhi; P. aeruginosa; E. 
Aerogenes; S. aureus; B. subtilis; 
M. luteus 
MIC values (expressed 
in µL of AuNPs): 
10 µL B. subtilis 
20 µL S. aureus 
30 µL M. luteus 
40 µL E. aerogenes, S. 
typhi and P. aeruginosa 
[41] 
Deinococcus 
radiodurans 
bacteria 
spherical, 
triangular and 
irregular 
intra- and 
extracellular 
~43.75 E. coli; S. aureus Data not shown [42] 
Pseudomonas 
veronii AS41G bacteria irregular extracellular 5–25 E. coli; S. aureus (+) Data not shown [43] 
Bacillus 
licheniformis bacteria spherical extracellular 
20–75 
(~38) E. coli; P. aeroginosa; B. subtilis Values not shown [44] 
Fusarium 
oxysporum f. sp. 
cubense JT1 
fungus n.a.0F extracellular ~22 Pseudomonas sp. Data not shown [45] 
Stoechospermum 
marginatum 
algae spherical to 
irregular 
extracellular 18.7–93.7 
P. aeruginosa; V. cholerae; V. 
parahaemoluticus; S. paratyphi; P. 
vulgaris; S. typhi; K. pneumoniae; 
K. oxytoca; E. faecalis(+); 
AuNPs more effective 
against E. faecalis > K. 
pneumoniae. Non-
effective against E. coli 
[46] 
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Streptomyces 
viridogens (HM10) bacteria 
spherical and 
rod intracellular 18–20 E. coli; S. aureus Data not shown [47]  
 CuNPs 
Shewanella loihica 
PV-4 
bacteria spherical extracellular 10–16 E. coli 
100 µg/mL Cu-NPs 
inhibits 86% of the 
bacteria 
[48] 
 SeNPs 
Enterococcus 
faecalis bacteria spherical extracellular 
29–195 
(~99) 
S. aureus (no observed activity 
against P. aeruginosa, B. subtilis 
and E. coli) 
Data not shown [49] 
 ZnONPs 
Glycosmis 
pentaphylla plant extract spherical extracellular 32–36 
S. dysenteriae; S. paratyphi; 
S. aureus; B. cereus 
At 100 µg/mL 
maximum inhibition is 
observed 
[50] 
Suaeda aegyptiaca plant extract spherical extracellular ~60 P. aeruginosa; E. coli; 
S. aureus; B. subtilis 
P. aeruginosa 
MIC and MBC: 0.19–
0.78 mg/mL 
E. coli 
MIC: 1.56–12.50 mg/mL 
MBC: 6.25–12.50 mg/mL 
S. aureus 
MIC and MBC:  
0.39–1.56 mg/mL 
B. subtilis 
MIC: 0.19–0.39 mg/mL 
MBC: 0.78–12.50 mg/mL 
[51] 
Pichia kudriavzevii fungus hexagonal extracellular 10–61 
E. coli(+); S. marcescens; 
B. subtilis(+); S. aureus (+);  
S. epidermis (++) 
Data not shown [52] 
Jacaranda 
mimosifolia plant extract spherical extracellular 2–4 
E. coli; 
E. faecium Data not shown [53] 
 CuONPs 
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Cystoseira trinodis algae spherical intracellular 6–7.8 E. coli; S. typhi; E. faecalis;  
S. aureus; B. subtilis; S. faecalis 
E. coli and S. aureus 
MIC: 2.5 µg/mL 
E. faecalis 
MIC: 5 µg/mL 
S. typhimurium 
MIC: 10 µg/mL 
[54] 
2 n.a. – information not available. 
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Biological methods take advantage of the defence mechanisms present in specific organisms 
(against high concentrations of metal ions) to produce metal-based nanoparticles. These methods 
include intracellular (e.g., bioaccumulation) or extracellular mechanisms (e.g., bioabsorption, 
biomineralization, complexation or precipitation) [55]. 
The use of fungi in the production of metal-based nanoparticles offers advantages for industrial 
scale production when compared to bacteria since these organisms have a higher resistance against 
the flow pressure and agitation of the bioreactors [56]. However, in recent years, most of the studies 
report the use of plant extracts because, in addition to the advantages mentioned above, its use 
facilitates the treatment of samples, the scale-up production, and the collection of the product of 
interest. 
3. Silver Nanoparticles (AgNPs) 
For a long time, silver has been used as an antimicrobial agent for wound healing, both in its 
solid state and with salt solutions to clean wounds. Nowadays, dressings impregnated with AgNO3 
can be found [57]. Silver exhibits very interesting properties due to its chemical stability, good 
conductivity, catalytic, and antibacterial activity. Moreover, nanoparticles made of silver (silver 
nanoparticles, AgNPs) are one of the most widely studied nowadays [58]. AgNPs have been applied 
in different fields such as textile, cosmetics, food industry, and biomedicine. In the biomedical field, 
they are gaining strength especially due to their applications as antimicrobial agents, as coating for 
medical devices, and as carrier for chemotherapeutic drugs [59]. Despite being widely studied, 
continuous research towards the development of more bio-sustainable synthesis methodologies is 
still needed, together with the disclosure of mechanisms involved in the toxicological effects AgNPs. 
3.1. Synthesis 
3.1.1. Conventional Chemistry 
Compared to other methods, chemical synthesis of AgNPs is relatively cheap and easy to 
implement at a large scale while maintaining a monodispersed size distribution. 
Among the variety of chemical methods available for the production, chemical reduction is the 
most widely used for this type of nanosystems. This process employs the use of three main 
components, (i) a metal precursor, (ii) reducing agents, and (iii) stabilizing agents [60]. Basically, two 
stages of nucleation and growth are involved (Figure 3). In this synthesis, the stabilizing agent can 
have a dual function, i.e., also acting as a reducing agent in the same reaction [61]. 
 
Figure 3. Process for the synthesis of AgNPs 
Appropriate average size, polydispersity, and shape of AgNPs can be achieved by controlling 
the nucleation stage, i.e., by monitoring the experimental parameters, such as the precursor used in 
the reaction, reducing agents, reagent concentration, pH, and temperature [62]65]. 
A critical step in the synthesis of AgNPs is their stabilization, especially in order to prevent 
agglomeration and oxidation processes. Therefore, one of the most common strategies is the use of 
stabilizing agents that are capable of protecting AgNPs. For the stabilization, chitosan, amine 
derivatives, thiols, or gluconic acid can be used. In addition, it has also been proven that the use of 
polymeric compounds, such as polyvinylpyrrolidone (PVP), polyacrylates, polyvinyl alcohol (PVA), 
polyacrylonitrile, polyacrylamide, or polyethylene glycol (PEG), is also useful. Finally, stabilization 
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can be achieved by electrostatic repulsion by incorporating a negative charge on the surface of these 
NPs mainly through citrate groups [62]. 
Among all the chemical methods to obtain AgNPs, the Creighton method is the most widely 
used because it allows to produce monodispersed and small size (around 10 nm) nanoparticles [63]. 
In this method, the precursor agent is AgNO3 and the reducing agent is NaBH4. The reaction that is 
carried out is as follows: 
2 AgNO3 + 2 NaBH4 → 2 Ag(s) + B2H6 + H2 + 2 NaNO3 (2) 
3.1.2. Green Chemistry 
Although chemical synthesis has the advantages of being of low cost and of high performance, 
the use of reducing agents is harmful. Therefore, methods that use environmentally friendly reagents 
have been developed. Special interest is the method using β-D-glucose as a reducing agent to cause 
the chemical reduction of AgNO3 salt. This method employs starch as a stabilizing agent (Figure 4). 
These green synthesis is able to obtain AgNPs under 10 nm of mean size [64]. 
 
Figure 4. Chemical reduction of AgNO3 salt from β-D-glucose  
Ho et al. described a synthesis method using ascorbic acid as a reducing agent for the reduction 
of AgNO3. They were able to obtain hybrid AgNPs inside a polylysine shell modified by different 
fatty acids. This green synthesis method was able to develop AgNPs of mean size between 2 and 5 
nm [65]. 
Nowadays eco-friendly methods of biosynthesis are being gradually replacing the traditional 
chemical synthesis with increasing publications about this topic in the last years. The biosynthesis of 
AgNPs uses the bases of chemical synthesis, but instead of a chemical entity, this takes advantage of 
the reductive properties of biological entities. 
The biosynthesis of AgNPs by bacteria able to produce reductase enzymes results from an intra- 
or extracellular process [66]. The intracellular biosynthesis uses facilitated transport of Ag+ ions into 
the bacterial cell. Bacteria can also produce AgNPs by transforming ionic Ag+ to neutral Ag0. In this 
case, additional step for recovery of AgNPs (as cell lysis) is required. Extracellular biosynthesis occurs 
outside bacterial cell either using bacterial biomass, the supernatant of bacterial cultures, or cell free 
extracts. An organic base is used in the supernatant to ensure the proper recovery of AgNPs by 
centrifugation and further resuspension [67]. Extracellular biosynthesis is preferred over the 
intracellular process as it does not require downstream processing one of the first bacteria used for 
the synthesis of AgNPs by culturing in high concentrations of AgNO3 was Pseudomonas stutzeri AG29, 
a silver-resistant bacterium isolated from a silver mine which reduces Ag+ to Ag0 with accumulation 
inside the cell [68]. Usually, AgNO3 is added to the organic base, and the mixture is incubated at 
optimized conditions [69]. The ionization of AgNO3 is described in the equation 
AgNO3(aq) ↔ Ag+(aq) + NO3−(aq) (3) 
Nitrate reductase is an enzyme produced by some bacteria activated at alkaline pH in the 
presence of a substrate (NO3−). This enzyme catalyses the reduction of nitrate to nitrite, illustrated in 
the equation [67] 
Ag+(aq) + NO3−(aq) + NADH + H+ + e− → Ag0(s) + NO2−(aq) + NAD+ + H2O(l) (4) 
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Jang et al. described that alkaline pH improves the yield of the reaction, also producing smaller 
sized particles in the pH range of 8 to 10 [70]. On the other hand, at acidic pH, Ag+ ions precipitate 
and AgNPs synthesis is hardly observed [70]. 
Fungi produce extracellular enzymes which are secreted outside the cell and are responsible for 
extracellular digestion of macromolecules followed by absorption of nutrients. This unique 
characteristic gives them great relevance in extracellular synthesis of AgNPs. After incubation and 
growth of colonies, fungi are usually separated from the aqueous medium containing extracellular 
enzymes. The first ones are discarded and AgNO3 is added to the medium. This mixture is then 
incubated usually at temperatures close to room temperature. Production of AgNPs follows the 
equations described above. The reaction of synthesis can be confirmed by change in the color of the 
medium [71]. Several aspects as medium properties, incubation time and temperature, AgNO3 and 
biomass concentrations and activity, are of crucial relevance. Zhao et al. evaluated the optimization 
of extracellular biosynthesis of AgNPs by fungi, being, pH 7, 25 °C, 1 mM AgNO3, and 15–20 g of wet 
cell filtrate the optimal conditions. The obtained nanoparticles were of spherical shape with a mean 
size recorded between 25 and 30 nm [72]. 
Synthesis of AgNPs using plant extracts is based on their relatively high levels of steroids, 
sapogenins, carbohydrates, and flavonoids, that act as reducing agents, as well as bio-capping 
compounds reducing agglomeration of nanoparticles and allowing a better size control [73]. In 
general, the obtention of AgNPs from plant extracts is a simple process. The freshly collected plant 
parts are cleaned with sterile water, dried in the shade, and powdered. For the preparation of the 
plant extract, the dry powder is boiled in deionized water. The resulted infusion is filtered until no 
insoluble material is present. A certain amount of plant extract is then added to the solution 
containing 1 mM AgNO3. AgNPs synthesis reaction may again be checked by a color change of the 
medium (usually to dark brown) and confirmed with the ultraviolet-visible (UV–Vis) spectra. AgNPs 
formed may be easily collected by repeated centrifugation processes at 12,000 rpm for 15 min [73]. 
3.1.3. Physical Methods 
There is a wide variety of physical methods for the synthesis of AgNPs, but 
evaporation/condensation is one of the simplest and best controlled. Moreover, laser ablation is also 
a method that allows to obtain a large number of nanoparticles in a short time. They are also the most 
widely used physical techniques. However, these methods are of high cost among other 
disadvantages, as the need to use a tubular furnace (which takes up a lot of space and consumes a 
large amount of energy) and the increasing temperature during the process requiring a long time to 
achieve thermal stability [60]. 
3.2. Characterization of AgNPs 
Numerous methods have been used to control and characterize AgNPs. The most often reported 
are UV–Vis spectrophotometry, X-ray diffractometry (XRD), transmission electron microscopy 
(TEM), and infrared spectroscopy (IR).  
UV–Vis spectrophotometry is usually performed at various time intervals during the reaction 
and provides valuable information about the success of AgNPs synthesis [74]. AgNPs have an 
extraordinary efficiency to absorb and disperse the light. This interaction with the light is produced 
because the electrons of the metal surface, when excited, experience a collective oscillation by 
characteristic wavelengths. These oscillations are known as the surface plasmon resonance. In the 
case of AgNPs, this appears around the wavelength of 400 nm; its exact position depends on the 
diameter, shape, and distribution of the nanoparticles [75]. 
XRD evaluates the crystalline nature of AgNPs, recorded in the 2θ range of 30–80° and provides 
confirmation about the morphology. XRD pattern of AgNPs usually reveals the formation of face-
centred cubic (FCC) structures of metallic silver. The prominent peaks are observed at 2θ = 38.19°, 
44.46°, 64.63°, and 77.34°, and correspond to the (111), (200), (220), and (311) planes, respectively [76]. 
Alternatively, the Debye–Scherrer equation allows for an approximate calculation of the average 
size as 
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𝐷 = 𝐾𝜆𝛽 cos 𝜃 (5) 
where D is the size (nm), λ is the wavelength of radiation (nm), β is the full width at half maximum 
(radians), and θ is the half of the Bragg angle (radians) [77]. 
TEM image allows the visualization of biosynthesized AgNPs morphology. Usually, AgNPs are 
spherical with a quite dispersed average size [76]. 
IR is usually carried out to identify key functional groups and to characterize biomolecules 
bound specifically on the synthesized AgNPs either by free amine groups, cysteine residues, or 
electrostatic attraction of carboxyl groups [78]. The biologically synthesized AgNPs are mixed with 
potassium bromide to make a pellet that is placed into the sample holder. Based on analysis, its 
assumed that these biomolecules and proteins may be involved in the capping stabilization. IR 
spectra vary with the characteristics of the organism/specie used in the AgNPs synthesis [71].  
Other procedures include scanning electron microscopy (SEM) and atomic force microscopy 
(AFM) also provide information on the size and size distribution. In addition, dynamic light 
scattering (DLS) determines size and polydispersity index and electrophoresis laser doppler is used 
to measure zeta potential (as an indirect measure of the surface electrical charge) of the nanoparticles. 
Moreover, field emission scanning electron microscopy (FESEM) provides information on the surface 
morphology, while energy-dispersive X-ray (EDX) is used for elemental analysis or chemical 
characterization. 
Zeta potential measurement is a valuable tool for determination of AgNPs stability and surface 
electrical charge of the aqueous colloidal suspensions. Balakrishnan et al. included zeta potential 
determination in their extensive AgNPs characterization which was determined to be about −9.56 
mV, indicating a slight repulsion of AgNPs [79]. Farhadi et al., on the other hand, recorded a value 
of about −35 mV. Since this latter value is higher than |30| mV stability of the colloidal AgNPs 
suspension is ensured, illustrating the repulsion between synthesized nanoparticles which prevents 
agglomeration phenomena [80]. Zeta potential values can be either positive or negative, however, its 
value is frequently negative probably due to the possible capping of bio-organic components present 
in the extract. AgNPs of negative zeta potential are usually associated with less antimicrobial activity 
[81]. 
3.3. Pharmacokinetics 
In general, biological membranes possess selective permeability allowing the entry of some 
biomolecules, mostly small and lipophilic molecules and metal ions. However, AgNPs 
pharmacokinetics has been shown to be dependent on various factors such as dose, exposure route, 
species, and gender of the tested organisms [82]. In order to determine these parameters, Bachler et 
al. developed a physiologically based pharmacokinetic model (PBPK) for humans to provide an 
evaluation about the exposure and risk assessment of AgNPs. However, to keep this PBPK models 
as simple as possible, they considered ADME (absorption, distribution, metabolism, and excretion) 
of AgNPs followed a first-order kinetic [83]. 
3.4. Absorption 
There are four potential administration routes for AgNPs in mammals. These include oral, 
dermal, pulmonary, or intravenous. As new promising agents against bacterial infections, AgNPs are 
being developed not only for topical, but also for systemic infections. For this reason, it is important 
to determine their pharmacokinetic parameters. Absorption of AgNPs through biological membranes 
depends on their physicochemical characteristics, as size and shape. 
3.4.1. Gastrointestinal Absorption 
In case of oral administration and during gastrointestinal absorption, AgNPs undergo a series 
of changes triggered by high temperatures, variable pH, changes of saline balance and enzymes in 
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the gastrointestinal tract. After gastric digestion, the number of nanoparticles drop significantly, 
rising back to original values after intestinal digestion. Reduction in number of particles is caused by 
their clustering promoted by the chloride present in the stomach. During intestinal digestion, these 
clusters are disintegrated back into single AgNPs. This phenomenon is believed to be caused by the 
increase in pH from gastric to intestinal medium. Results like these indicate that, under physiological 
conditions, AgNPs reach the intestine mostly in their original form [84]. 
Although most of AgNPs reach the intestine, its gastrointestinal absorption rates are extremely 
low, as proved by Bachler and colleagues, who concluded that after oral administration of AgNPs, 
the intestinal absorption fraction was about 0.12% to 0.88% in humans and ionized silver (Ag+) 
presented a fraction of approximately 5% in rats [83]. The low absorption of AgNPs after an oral dose 
may be associated with the binding of nanoparticles to non-digestible food components resulting in 
a higher fecal excretion of silver [85]. 
3.4.2. Pulmonary Absorption 
Absorption from the alveoli to the bloodstream is mostly dependent on size of the nanoparticles. 
While ultrafine AgNPs dissociates rapidly and silver spreads to the blood capillaries, larger or 
agglomerated AgNPs are retained in the lungs. The remaining AgNPs in the alveoli are rapidly 
eliminated through local macrophages phagocytosis [86]. 
In order to determine absorption fractions of AgNPs, Bachler et al. used as reference the 
concentrations needed to cause argyria (a condition that occurs after prolonged exposure to silver 
and is characterized by irreversible purple to grey coloration of skin/eyes) after pulmonary or 
intestinal uptake. According to these authors, this value can be up to 3.75 times higher to an oral dose 
when compared to an inhaled dose, which suggests a more extensive lung absorption. During their 
experiments, Bahler et al. obtained absorption fractions of 20.1% for inhalation and 3.25% for oral 
absorption, which are consistent with the values referred above [86]. 
3.4.3. Cutaneous Absorption 
The first route for dermal penetration involves transport through the stratum corneum, either 
by transcellular (diffusion through the cells) or intercellular pathway (diffusion through the gaps 
between corneocytes). The second route for epidermal penetration includes the entry via skin 
appendixes as hair follicles and sweat glands [87]. 
AgNPs, as other metallic nanoparticles, accumulate in the follicle where they form a deposit 
which cannot be removed by natural desquamation or body washing. These deposits allow a gradual 
absorption of nanoparticles from the follicles to the blood capillaries [88]. According to Larese et al., 
AgNPs can penetrate intact human skin. However, the amount capable to penetrate in compromised 
skin has been reported to be 5 times greater than in the intact skin [89]. 
3.5. Distribution 
Accumulation of AgNPs in the tissues is dependent on the administration route, e.g., high levels 
in skin after dermal administration or in the lungs during pulmonary administration. After oral 
administration, AgNPs reach high concentrations in stomach and in small intestine. After oral 
administration and absorption, silver undergoes the first-pass metabolism with further excretion in 
the bile, reducing systemic distribution in the body tissues [90]. 
After intravenous injection, concentration-time curves revealed a rapid decline in silver 
concentration during the first 10 min which indicates a fast distribution of AgNPs to tissues followed 
by stabilization. Although silver distributes to all organs, it achieves higher accumulation in the 
spleen and liver after a single dose injection. Prolonged treatments result in a slight decrease in liver 
accumulation with AgNPs depuration and excretion through the bile and a redistribution of silver to 
other organs as kidney, heart, lungs, testes, and brain [91]. 
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3.6. Metabolism and Excretion 
Stabilization of AgNPs by proteins adsorbed onto their surface blocks dissolution of silver 
making impossible the formation of new soluble silver species. Instead, stable AgNPs undergo direct 
complexation into silver sulphide particles which accumulate in the tissues [83]. Activation of 
metallothioneins in the liver may also be pointed out as a reason for AgNPs accumulation in this 
organ. These small proteins that bind in a variable size of 7 KDa present a high number of thiol groups 
which are involved in detoxication of heavy metals in liver, but also in other organs as kidneys, 
intestine, and brain [91]. 
The elimination of AgNPs is slow. The fraction of AgNPs excreted by the kidneys can be 
considered negligible, being less than 0.01%, while biliary excretion is the main route of silver 
clearance, being responsible for more than 50% [92]. This route includes the complexation of silver 
with glutathione (GSH) generating silver-GSH complexes [83]. However, elimination will be 
governed by the tissue where the AgNPs are found, and also by the dose and the particle size. As 
such, AgNPs have shown an elimination half-life that will vary from 29 days to more than 260 days 
after oral administration [93]. 
3.7. Antimicrobial 
Despite several approaches that have been made over the years, the precise mechanism of action 
of AgNPs is still not fully understood. The antimicrobial action of AgNPs is linked to four main 
mechanisms: (i) attraction to bacterial surface, (ii) destabilization of bacterial cell wall and membrane 
with change in its permeability, (iii) induction of toxicity and oxidative stress by generation of ROS 
and free radicals, and (iv) modulation of signal transduction pathways [62]. 
Adhesion of AgNPs onto the surface of bacteria is described by many authors as the first step of 
a complex mechanism of bacterial inhibition. AgNPs adhesion is highly influenced by their size, but 
also by their zeta potential. Depending on the method for their synthesis, AgNPs may have a positive, 
neutral, or negative surface charge. Abbaszadegan et al. demonstrated that by varying the surface 
charge of nanoparticles, a marked fluctuation of the antibacterial activity occurs. Since bacterial 
surface shows a slightly negative charge, positively charged AgNPs are strongly attracted to the 
surface of the bacteria, resulting in increased antibacterial activity (Table 2). On the other hand, 
neutral or negatively charged nanoparticles have a significantly decreased antibacterial effect. 
However, an increase in the concentration of AgNPs allows the attenuation of electrostatic repulsion 
through a bacterial surface saturation method [94]. 
After adhesion onto the bacterial surface, AgNPs can interact with the cells via two different 
mechanisms. Smaller AgNPs penetrate directly into the cell, while larger nanoparticles are retained 
outside the bacteria. In both cases, AgNPs continuously release Ag+ ions. These ions bind to cell 
membrane structures destabilizing the membrane potential and causing proton leakage. Cell wall 
destabilization highly increases bacterial permeability, allowing larger AgNPs to enter the cell [95]. 
Once inside the cell, AgNPs and Ag+ ions interact with numerous structures and biomolecules as 
proteins, lipids, and DNA, resulting in cell dysfunction. AgNPs are well known by their high capacity 
to produce reactive oxygen species (ROS) and free radicals as hydrogen peroxide (H2O2), superoxide 
anion (O2−), and hydroxyl radical (OH•). Although ROS occur naturally in bacteria as a result of 
cellular respiration, under normal circumstances bacteria have defense mechanisms—such as 
glutathione (GSH), superoxide dismutase, and catalase—that act as antioxidant enzymes and 
eliminate these toxic species. High concentrations of Ag+ released by AgNPs produce extreme levels 
of oxidative stress (Figure 5). Even though antioxidant enzymes remove some of the released ions, 
these are not enough to neutralize the AgNPs amount [96]. These species interact with respiratory 
chain proteins on the membrane and inactivate enzymes due to their high affinity to phosphates, 
thiol, and carboxyl groups [97]. Their link to phosphate groups inhibits phosphorylation of proteins 
which is frequently involved in enzymatic activation, ultimately resulting in inhibition of bacterial 
growth. Dephosphorylation of tyrosine residues of protein was also been implicated in disruption of 
biosynthesis and transport of exopolysaccharide and capsular polysaccharide to the membrane, 
thereby disruption of cell cycle [62]. Additionally, Ag+ can intercalate DNA strands forming 
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complexes with nucleic acids between the purine and pyrimidine base pairs, disrupting H-bonds 
between them [96]. 
 
Figure 5. Schematic representation of AgNPs mechanism of antimicrobial activity 
3.8. Other Pharmaceutical Properties 
Bactericidal properties of AgNPs are the most widely studied, but a wide variety of other 
biomedical properties—such as antifungal, antiviral, antiamebial, anti-cancer, anti-angiogenic, and 
anti-inflammatory activity—are also being exploited [59]. New antifungal agents are also a demand, 
in particular, for immunosuppressed patients. AgNPs have a high antifungal potential, for example 
in Candida albicans infections, AgNPs stabilized with dodecyl sulphate show a better activity than 
conventional treatment [98]. AgNPs also show antiviral properties. In the case of activity against HIV-
1 AgNPs have demonstrated anti-retroviral ability in addition to a potent virus inhibition effect. They 
have also proven to be efficient inhibitors against hepatitis B virus (HBV) [99]. When associated with 
drugs capable of crossing the blood–brain barrier such as diazepam, AgNPs also showed antiamebial 
activity [100]. 
Also, due to the cytotoxic effects of AgNPs, they are seen as a promising alternative in cancer 
therapy. AgNPs have been used against breast, hepatocellular, or lung tumors, but also as carriers of 
anticancer drugs in chemotherapy. Faedmaleki et al. showed that AgNPs are able to exhibit a 44-fold 
inhibitory effect on a HepG2 liver cancer cell line with an IC50 of 2.8 ppm (µg/mL) compared to a non-
carcinogenic cell line with an IC50 of 121.7 ppm [101]. AgNPs demonstrated to be antiangiogenic and 
antiproliferative [59]. AgNPs also showed anti-inflammatory properties by inhibiting pro-
inflammatory cytokines [102]. 
3.9. Toxicity Assessment 
The toxicity of AgNPs is directly related to their physicochemical properties such as surface 
charge, solubility, shape, size, specific surface area, and agglomeration status. As AgNPs have high 
surface area when compared to bulk counterparts, their reactivity in biological media is also high, 
with higher risk of toxicological events [103]. AgNPs with a negative surface charge have shown 
lower toxicity than positively charged nanoparticles [104]. Similarly, when AgNPs dissolve and lose 
their spherical structure, their toxicity increases. However, further studies are required to assess 
whether the toxicity of AgNPs is produced by the nanoparticles themselves or by the silver ions that 
are released. The shape is also a relevant element to assess the toxicity as there are more toxic forms 
of AgNPs than other types of nanoparticles, being nanospheres with less toxicity.
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Table 2. Antibacterial applications of silver-based nanoparticles, with respective mminimum inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC) values 
Nanoparticles Efficacy  
Physicochemical 
Characteristics of the 
Nanoparticles 
Production Method Therapeutic Efficacy 
MIB and MIC 
Values Reference 
Coliforms bacteria in water 
and fecal media 
Monodispersed 
spherical AgNPs 
Average size 20–60 
nm 
ζ-potential (−30 to 
−15) mV 
(Chemical reduction) 
Green method from extracts of 
Olea Europaea leaves (Leccino and 
Carolea), pH 7 or 8 
Antibacterial activity evaluated with 
total bacteria detection by plate 
count techniques. 
Conducted trials of toxicology and 
cytotoxicity (WST-8 assay, lactate 
dehydrogenase (LDH) assay, comet 
assay) 
Data not shown [105] 
Human pathogenic Gram-
positive and Gram-negative 
bacteria: Staphylococcus 
aureus, Escherichia coli, 
Klebsiella pneumoniae, 
Pseudomonas aeruginosa and 
methicillin-resistant 
Staphylococcus aureus 
(MRSA)) 
Spherical or rarely 
polygonal AgNPs 
Average size 44 nm 
(Chemical reduction) 
Green method 
AgNPs were synthesized using 
Picea abies L. stem bark extract, 
and sing different surfactants 
Effective antioxidant activity 
Staphylococcus 
Aureus: (MIC 
0.05 mg/mL, 
MBC 1.57 
mg/mL) 
MRSA: MIC 0.09 
mg/mL, MCB 
0.25 mg/mL) 
E. coli MIC: 0.23 
mg/mL, MCB 
0.31 mg/mL 
Klebsiella 
pneumoniae MIC 
0.63 mg/mL, 
MCB: 1.18 
mg/mL 
Pseudomonas 
aeruginosa MIC 
0.16 mg/mL, 
[106] 
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MCB 0.31 
mg/mL 
Staphylococcus aureus, 
Escherichia coli, and 
Pseudomonas aeruginosa  
Spherical shape 
Average size 430 nm 
ζ-potential −15.2 mV 
(Chemical reduction) 
Green method. synthesized using 
terpenes rich extract of Lantana 
camara L. leaves 
Antibacterial aactivity assessed 
using agar-well diffusion method  
Conducted trials of Brine shrimp 
cytotoxicity and antioxidant 
potential 
Data not shown [107] 
Staphylococcus aureus, 
Escherichia coli 
Spherical shape 
Average size 
between 10–26 nm  
(Chemical reduction) 
Green method. AgNPs were 
synthesized using Acalypha 
wilkesiana extract 
Agar-well diffusion method was 
used to evaluate antibacterial 
activity 
Data not shown [108] 
Staphylococcus aureus, 
Escherichia coli (Extended-
Spectrum Beta-lactamase 
(ESBL), and MRSA  
Average size  
77.68 ± 33.95 nm  
ζ- potential  
−34.6 ± 12.7 mV 
UV–Vis wavelength: 
420 nm 
(Fungus-mediated Synthesis) 
Green method. AgNPs were 
synthesized using 
Fusarium oxysporum 
MIC, antibacterial combination 
assay 
Antimicrobial disk susceptibility test 
and time-kill curve assay used to 
evaluate antibacterial activity. Also 
conducted trials of cytotoxicity 
assay in human red blood cells 
MRSA MIC 0.212 
mg/mL 
ESBL MIC 0.106 
mg/mL 
[109] 
Escherichia coli, Salmonella 
typhi, Staphylococcus aureus,  
Vibrio cholerae, Enterococcus 
faecalis, 
Hafnia alvei, Acinetobacter 
baumannii  
Average size: first 
method: 428.2 ± 197.0 
second method:  
190.1 ± 102nm 
Polydispersity index: 
0.4 
ζ-Potential first 
method −22.1 ± 0.9 
and second method 
−26.1 ± 1.4 mV, 
UV–Vis wavelength 
412 and 418 nm.  
(Chemical reduction) 
Green method. AgNPs were 
synthesized using Andrographis 
paniculate, aqueous, and ethanolic 
extracts 
The zone of inhibition (ZOI), MIC, 
trypan blue dye exclusion assay, 
also conducted trials of CellToxTm 
green assay, LPO assay, 
hemocompatibility assay and in 
vivo intravenous delivery of AgNPs 
and Investigation of liver and 
kidney function biomarkers 
S. typhi MIC 
0.125 and 0.250 
µg/mL 
H. alvei MIC 
0.125 and 0.125 
µg/mL 
E. faecalis MIC 
0.250 and 0.250 
µg/mL 
A. baumannii 
MIC 0.250 and 
0.125 µg/mL 
E. coli MIC 0.125 
and 0.250 µg/mL 
[110] 
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V. cholera MIC 
0.125 and 0.125 
µg/mL 
Staphylococcus aureus, 
Bacillus subtilis, and 
Escherichia coli 
Spherical shape 
Average size  
13.2 ± 2.9 nm 
ζ-potential −16.6 mV 
UV–Vis wavelength 
420 nm  
(bacterial-mediated 
Synthesis) 
Green method. AgNPs were 
synthesized using 
acidophilic actinobacterial SH11 
Disc diffusion, MIC and 
LIVE/DEAD analyses to evaluate 
antibacterial activity 
S. aureus MIC  
40 µg/mL 
E. coli MIC  
70 µg/mL 
B. subtilis MIC  
40 µg/ml 
[111] 
Staphylococcus aureus, 
MRSA, Escherichia coli, and 
Pseudomonas aeruginosa 
Average size 
between 6.28–9.84 
nm, UV–Vis 
wavelength range of 
391– 403 nm 
(Chemical reduction) 
Method into the lamellar space 
layer of montmorillonite/chitosan 
(MMT/Cts) on using NaBH4  
Disc diffusion method to evaluate 
antibacterial activity 
Data not shown [112] 
Bacillus subtilis and MRSA 
Average size 
between 10 and 35 
nm 
Polydispersity index 
0.2, ζ-potential of −30 
mV UV–Vis 
wavelength of 421 
nm 
(bacterial-mediated Synthesis) 
synthesized AgNps from the 
exopolysaccharide of recently 
recovered bacterial strain CEES51 
Zone Inhibition Assay, MIC, MBC, 
Antibiofilm activity determination, 
colony-forming unit determination 
to estimate the bacterial 
susceptibility against AgNPs, 
intracellular reactive oxygen species 
production by AgNPs inside 
bacterial cells 
B. subtilis MIC 10 
µg/mL, MBC 50 
µg/mL 
MRSA MIC 10 
µg/mL, MBC 
12.5 µg/ml 
[113] 
Vibrio natriegens  
Average size 10 ± 5 
nm, 30 ± 5 nm, 60 ± 5 
nm, 90 ± 5 nm  
UV–Vis wavelength 
ranged from 400–420 
nm 
(Chemical reduction) 
Green method. AgNPs of different 
size were synthesized using casein 
hydroly- sate as a reducing reagent 
and sodium hydroxide (NaOH) as 
a catalyst 
MIC, MCB, reactive oxygen species 
production by AgNps inside 
bacterial cells 
MIC 1.0–11.5 
µg/mL 
MBC 1.1–11.7 
µg/ml 
[114] 
Staphylococcus aureus and 
Escherichia coli 
Average size 20 nm  
UV–Vis wavelength 
of 390 nm 
(Chemical reduction) 
Green method 
The agar diffusion method 
was used for the antimicrobial 
assay. And the antioxidant activity 
Data not shown [115] 
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AgNPs were synthesized using 
Ultrasound assisted fabrication 
and fenugreek seed 
extract as a reducing and capping 
agent 
Staphylococcus aureus, 
Shigella dysenteriae, and  
Salmonella typhi 
Average size from 60 
to 80 nm 
(fungus-mediated 
Synthesis) 
Green method. AgNPs were 
synthesized using 
Penicillium oxalicum 
Antimicrobial potential in liquid 
broth by optical density 
measurements, and disc diffusion 
method 
Data not shown [116] 
Pseudomonas aeruginosa, 
Klebsiella pneumoniae, and 
Escherichia coli 
MRSA 
Average size 10 to 40 
nm  
ζ-potential −29 ± 0.11 
mV 
(Chemical reduction) 
Green method. 
AgNPs were synthesized using 
lyophilized Seabuckthorn 
MIC, MCB, evaluation of P. 
aeruginosa biofilm, anti-quorum 
sensing inhibition assay. Also 
conducted trials of cytotoxicity 
assay with human dermal fibroblast 
P. aeruginosa 
MIC 2 µg/mL, 
MBC 4 µg/mL 
E. coli MIC 4 
µg/mL, MBC 8 
µg/mL 
S. aureus MIC 4 
µg/mL, MBC 8 
µg/mL 
K. pneumoniae 
MIC 8 µg/mL, 
MBC 16 µg/mL 
[117] 
Escherichia coli- 25922 
and multidrug-resistant 
pathogens of Pseudomonas 
aeruginosa and 
Acinetobacter baumannii 
Spherical shape 
Average size from 35 
to 50 nm, UV–Vis 
wavelength of 326 
nm 
(Chemical reduction) 
Green method. 
AgNPs were synthesized using 
Sisymbrium irio extract 
The agar diffusion method 
was used for the antimicrobial assay Data not shown [118] 
Bacillus cereus, 
Staphylococcus aureus, 
Micrococcus Luteus, 
Bacillus Subtilis, Enerococcus 
Sp. 
Spherical shape  
Average size 10 nm  
UV–Vis wavelength 
of 432 nm 
(Chemical reduction) 
Green method. 
AgNPs were synthesized using 
Tamarindus indica natural fruit 
extract 
The agar diffusion method 
was used for the antimicrobial assay 
Data not shown [119] 
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Pseudomonas aeruginosa, 
Salmonella typhi, Escherichia 
coli, and 
Klebsiella pneumonia 
Escherichia coli, Bacillus 
subtilis, Pseudomonous 
fluorescence and Salmonella 
typhi  
Average size 21 nm  
ζ-potential −32 mV  
UV–Vis wavelength 
of 421nm 
(Chemical reduction) 
Green method. 
AgNPs were synthesized using 
Ficus religiosa leaf extract 
Kirby–Bauer Disk diffusion method 
and the growth inhibition curve of 
E. coli was examined after the 
exposure of AgNPs. Also conducted 
trials of anti-cancer activity and in 
vivo toxicity 
Data not shown [120] 
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It has been firstly assumed that AgNPs would be less toxic to mammalian cells than to bacterial 
cells [121]. It has been however demonstrated that AgNPs have no such selectivity. AgNPs also 
induce toxicity to mammalian cells as demonstrated in different studies showing toxicity in 
hepatocytes and neuronal cells [122]. Toxicity of AgNPs to humans is caused by different 
mechanisms. On one hand, it seems to be associated with the oxidative nature. Due to their 
interaction with proteins and enzymes with thiol groups (in superoxide dismutase) which are key in 
the antioxidant defence mechanisms of cells. On the other hand, AgNPs are able to stimulate DNA 
damage, due to their genotoxic potential, breaking DNA chains and causing chromosomal 
aberrations [123]. Regarding aquatic media, some studies have been reported. Harmon et al. reported 
the kinetics of AgNPs of different sizes. They have shown that the aqueous media with high 
conductivity increase the risk of AgNPs aggregation and decrease toxicity. Toxicity values were 
greater for 20 nm rather than nanoparticles between 50 and 80 nm [124]. Moreover, using a green 
alga model (Chlamydomonas acidophila) it has been reported that after 24 h of exposure, the chlorophyll 
content and cellular viability of the alga decreased significantly and their ROS production increased 
proportionally to the concentration of AgNPs [125]. Concentration-dependent toxicity has also been 
observed in zebra fish, causing an increase in mortality rates [126]. In this organism, AgNPs were 
able to induce cardiac and morphological abnormalities leading to death in exposure to high 
concentrations [126]. 
The bioavailability of AgNPs depends on the soil [127]. AgNPs are less retained in glass beads, 
quartz or artificial soils while they are easily retained in natural soils [128]. 
4. Copper and Copper Oxide Nanoparticles (CuNPs, Cu2ONPs and CuONPs) 
Cooper is a semiconductor material considered to be an excellent candidate for the synthesis of 
metal-based nanoparticles. Besides being highly resistant to heat, it is also robust, stable, cheap and 
easily synthesized [94,95]. 
4.1. Synthesis 
CuNPs and CuONPs can be synthesized by various processes. Among all, biocompatible 
processes emerged as the most investigated in the past few years. Independently of the selected 
method, during synthesis, CuSO4, CuCl2 · 2H2O, Cu (NO3) 2 or Cu (CH3COO)2 are the most frequently 
used copper precursors. Synthesis of CuONPs is divided in two steps illustrated below [95]: 
Cu2+ + 2e− reduction Cu0 + Air (O2) oxidation CuO (6) 
The first reaction consists in the reduction of the ionic precursor (Cu2+) with formation of Cu0 
which is highly unstable in the presence of oxygen, and for this reason, it is oxidized to CuO. 
Occurrence of the reaction may be assessed by observing a color change of the solution: bleaching of 
the solution with Cu0 formation which changes again, usually to a brownish tone after the conversion 
to CuO [95]. 
4.2. Pharmacokinetics 
Since copper is an essential microelement present in all tissues in the human body, its 
distribution and accumulation are hard to assess [96]. For this reason, to date no work has been 
published regarding pharmacokinetics of CuONPs. However, a study reported pharmacokinetics of 
Cu2+ and Zn2+ after an intravenous dose of a drug containing these elements in rats. The authors 
determined the baseline copper concentration in blood (1.09 ± 0.04 mg/mL) by subtracting basal 
values from total metal levels. From the obtained results, copper is distributed to all tissues having 
affinity to specific transporters that will mediate its entrance in the cells. Similarly, mammalian cells 
possess Cu-efflux transporters that control the excess of Cu in the intracellular medium, maintaining 
copper homeostasis [97,98]. 
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4.3. Pharmacodynamics 
It has been suggested that CuNPs have a greater ability to inhibit bacterial growth because of 
their direct contact with bacterial cells (attributed to better electron transfer between bacteria and 
CuNPs). In this case, the slightly negative bacteria and the metallic nanoparticles act as electron 
acceptors, both contributing to the electron transfer and rupture of the bacterial membrane. 
Moreover, light irradiation can lead to excited electron-holes pairs in CuO, which show that the 
bacteria inactivation could also be due to a photocatalytic process. In addition, antibacterial 
characteristics displayed by copper are a result of cellular damage after contact between released Cu2+ 
ions and bacterial membrane. 
However, CuNPs are more instable and have high susceptibility to oxidation. This problem was 
overcome by the conversion of CuNPs to CuONPs, the latter having greater stability but with slightly 
less activity [99]. 
4.4. Pharmaceutical Properties  
CuONPs have shown antimicrobial effects (Table 3). The mechanism of antibacterial activity of 
CuONPs is not well elucidated yet, but it is believed that it involves bacterial cell wall adhesion 
triggered by electrostatic interactions. Dissociation of Cu2+ induces the generation of ROS that contact 
with cellular membranes. These ions also have the capacity to enter the cell, causing membrane 
damage which is associated with disruption of cells internal content and bacterial cell leakage [11,99]. 
Moreover, their antibacterial activity has been studied particularly against microorganisms such 
as E. coli, V. cholera, P. aeruginosa, S. typhus, S. aureus. E. faecalis, B. subtilis and S. faecalis [100,101]. 
Mirhosseini confirmed in vitro that CuONPs had antibacterial properties, reducing significantly the 
growth of S. aureus and P. aeruginosa at the concentration of 500 µg/mL and also showing growth 
reduction percentages by 24% for S. aureus and 7.9% for P. aeruginosa [129]. Yoon et al. examined the 
antimicrobial effect of copper nanoparticles which reduced by 90% E. coli and B. subtilis at the 
concentrations of 33.49 µg/mL and 28.20 µg/mL, respectively [130]. Kumar et al. also synthesized 
colloidal CuONPs from glucose, starch and CuCl2 and its antibacterial properties were assessed 
against E. coli (Gram-negative), S. epidermis (Gram-positive), a methicillin resistant S aureus (superbug 
MRSA) isolate and the spore-forming Bacillus megatherium. Results showed that treatments of 
CuONPs, with elemental copper concentrations of 0.0113 and 0.00113 113 mol L−1 kill all the 
microorganisms assessed [131]. 
Moniri et al. synthesized ultra-small CuONPs obtaining a minimum inhibitory concentration 
(MIC) (derived from both precursors) against E. coli and S. aureus of 3.75 and 2.50 mg/mL, respectively 
[132]. Ishaque and Kannabiran biosynthesized CuONPs which showed inhibited the bacterial 
pathogens B. cereus, P. mirabilis and A. caviae even at 5 µg/mL concentration [133]. 
4.5. Toxicity Assessment 
Few studies have addressed the biosafety effects of CuNPs on the embryogenesis of vertebrates. 
Zhang et al. observed that CuNPs can develop mental abnormalities in zebrafish embryos (tail and 
spinal cord flexure and truncation, yolk sac edema and fin abnormality, head and eye hypoplasia, 
and no swim bladder and reduced digestive gut) treated even with 0.15 mg/L (2.3 µM) concentration. 
High mortality was observed in embryos treated with 0.5 mg/L (7.8 µM) CuNPs, and the mortality 
increased in a dose-dependent manner. Also, death was observed in embryos treated with 1 mg/L 
(15.6 µM) CuNPs even at 24 h post-fertilization [134]. In the same way, Yet et al. investigated the toxic 
effects of CuNPs on lateral-line hair cells of zebrafish embryos. CuNPs were found to cause toxic 
effects in a dose- dependent manner. Values of the 96 h 50% lethal concentration (LC50) of CuNPs 
were 2.61 ppm (41.1 µM). Embryos were unable to survive at ≥5 ppm (78.8 µM) of CuNPs and the 
number of FM1-43-labelled hair cells and the microstructure of hair bundles was significantly 
impaired [≥0.01 ppm (0.16 µM)] [135]. On the other hand, in vitro air–liquid interface studies, provide 
data on nanotoxicity of metal oxides. Therefore, Jing and colleagues evaluated the toxicity of CuONPs 
in human bronchial epithelial cells (HBEC) and lung adenocarcinoma cells (A549 cells). They found 
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that CuONP exposures significantly reduced cell viability, increased lactate dehydrogenase (LDH) 
release and elevated levels of reactive oxygen species (ROS) and IL-8 in a dose-dependent manner [136]. 
5. Gold Nanoparticles (AuNPs) 
AuNPs are colloidal or clustered particles composed of a gold core, an inert and biocompatible 
compound [137]. One of the advantages of these particles are their synthetic versatility, which allows 
the control of their size, shape and surface properties. Furthermore, their coating can be modified to 
control particle solubility, stability and interaction with the environment. Also, the particle surface 
can bind thiols and amines, providing functional groups to the AuNPs for labelling, targeting and 
conjugating pharmacologic molecules [138]. Their unique characteristics make them a material of 
extreme interest in the medical field due to their optical and electronic properties of Au. Some of the 
major areas of application of AuNPs include biosensors and bio-imaging, drug delivery systems, and 
also the treatment of some cancers. Meanwhile, some researchers have been interested in the potential 
antibacterial activity of AuNPs since this material is less toxic to mammalian cells compared to 
AgNPs, the most common nanoparticles employed as antimicrobial agents (Table 4) [40]. 
5.1. Synthesis 
There are several methods for the synthesis of AuNPs, including chemical, physical and 
biological pathways, all of them are based on the reduction reaction of chloroauric acid (HAuCl4) 
followed by agglomeration in the presence of a stabilizing agent [139]. 
AuCl−4 + 3e− reduction Au0 + 4Cl− (7) 
The reaction is easily detected by the color change of the solution from pale yellow to pinkish 
red color caused by the alteration in the surface plasmon resonance of the newly formed AuNPs. This 
is due to the fact that at nanosize, the surface electron cloud of gold vibrates, absorbing the 
electromagnetic radiation of a certain wavelength. In most cases, a peak absorption of AuNPs 
between 500 and 600 nm (~521 nm) is observed [40]. 
5.2. Pharmacokinetics 
AuNPs biodistribution is dependent on many variables, including size and geometry of 
nanoparticles, surface chemistry and type of stabilizing agent [140]. 
Although AuNPs distribute through all the organs, they present a size-dependent distribution 
pattern with smaller nanoparticles showing a more widespread distribution. AuNPs remain in the 
body for long periods of time, being eliminated very slowly in the faeces and urine.  
After intravenous injection, AuNPs are preferably accumulated in some organs, mostly in the 
liver, followed by spleen and lungs. Their biodistribution presents a first phase of distribution 
followed by a second phase of redistribution and elimination. Balasubramanian et al. described a 
redistribution time of one month after intravenous injection in rats. During this period, they observed 
an increase in the levels of gold in the kidneys, testis and blood along with persistently high levels of 
gold in the liver, spleen and adrenal glands [141]. 
5.3. Pharmacodynamics 
AuNPs are active against Gram-negative and Gram-positive bacteria, namely E. coli, P. 
aeruginosa, S. typhi, Serratia sp, K. pneumoniae, S. aureus, B. subtilis and E. faecalis, among others (Table 
3). The fact that AuNPs are relatively inert implies that they exhibit no apparent intrinsic antibacterial 
activity. Thus, it is understood that their main mechanism of bacterial toxicity is based on direct 
adherence of AuNPs onto the bacterial surface driven by electrostatic forces. This mechanism is 
highly dependent on nanoparticles size, typically with smaller nanoparticles showing lower MIC. 
From their adhesion results alterations of membrane potential, inhibition of adenosine 
triphosphatase (ATPase) activity (resulting in inhibition of ATP synthesis) and inhibition of tRNA 
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binding in subunit of the ribosome. This phenomenon will block instrumental metabolic processes 
which result in the loss of cellular integrity [40]. 
Due to their low reactivity, AuNPs show ion release and ROS production as a minor mechanism 
of action. Therefore, they need to be achieve higher concentrations to produce the same antibacterial 
effect as other metal-based nanoparticles (for example AgNPs) [142]. In this sense, Zhang et al. 
showed that to produce the small zone of inhibition for S. aureus, AuNPs need a concentration of 197 
µg/mL, whereas AgNPs need small concentrations as 4.86 µg/mL [142]. 
5.4. Other Pharmaceutical Properties 
Pharmaceutical properties of AuNPs have been recently studied. Besides their antibacterial 
activity, AuNPs have antioxidant and anticancer activities. AuNPs are seen as a relatively new agent 
in cancer therapy because these nanoparticles minimize side effects and limit the damage in healthy 
cells. The mechanism of action is not well known, but researches have reported cellular 
internalization of AuNPs by cancer cells due to their surface specific characteristics. Due to the optical 
and electronic properties of gold, AuNPs have been also studied for biomedical applications, such as 
nanodelivery (drugs, genes), imaging, (photoacoustic imaging, computed tomography), therapy 
(photothermal therapy and radiosensitization) and diagnostics (chemical and biological sensing) 
[143]. 
5.5. Toxicity Assessment 
Despite the potential applicability of AuNPs, some doubts remain about their potential toxicity. 
The mainstream opinion that AuNPs are non-toxic is recently disputable. The potential toxicity in 
vitro and in vivo of AuNPs appears to be multi-faceted and difficult to predict. Some authors 
investigated in vitro toxicity of AuNPs, and the results showed that these nanoparticles induce 
generation of endogenous ROS after entering the cells and then lead to further oxidative stress-related 
cytotoxicity such as DNA damage, cell death and cell cycle arrest in consequence. As an example of 
an in vitro cell viability assay, AuNPs with a size of 15–20 nm decrease cell viability from 100% at a 
concentration of 0.1 ppm to less than 40% at a concentration of 10 ppm, showing their potential 
toxicity [144]. On the other hand, some researches have reported the non-toxicity of the AuNPs in 
vitro testing different cell lines, nanoparticle shape and surface groups, and doses [145]. 
The in vivo toxicity has been studied in some animal models as mice, rat, zebrafish, shrimp, 
snail, clam and pig, assessing different nanoparticle shapes, surface groups and doses. The obtained 
results did not report side effects or lethal toxicity. However, most studies report higher 
bioaccumulation in liver, and a few authors observed accumulation in other organs like lung, brain, 
heart and kidneys. However, neither the mechanism of toxicity nor doses have been described yet 
[145]. 
The environmental impacts of AuNPs still remain unknown. There are some studies about 
phytotoxicity and aquatic toxicity. AuNPs can exert phytotoxicity to aquatic environment at a 
concentration of gold in the form of nanoparticles of 6 × 10−6 M [146]. Moreover, acute toxicity of 
aquatic organisms, such as fish and arthropods, has been studied. The results showed that fishes are 
more sensitive than smaller organisms (as daphnia), arthropods can undergo molting in order to cope 
with the particles adhered onto their shell. For the majority of fish species exposed to ionic gold (2.44 
mg/L), 50% of mortality has been reached between 12 h and 24 h [147]. 
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Table 3. Antibacterial applications of Cu and CuO-based nanoparticles, with respective minimum inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC) values. 
Nanoparticles 
Efficacy  
Physicochemical 
Characteristics of the 
Nanoparticles 
Production Method Therapeutic Efficacy 
MIB and 
MIC 
Values 
Reference 
Staphylococcus aureus 
Pseudomonas 
aeruginosa 
Data not shown Data not shown 
Ultrasound increased the antibacterial effect of 
CuO nanoparticles against S. aureus and P. 
aeruginosa 
Data not 
shown 
[129] 
E. coli 
S. epiderdimis  
methicillin 655 
resistant S.s aureus 
(superbug MRSA) 
isolate  
Spore-forming Bacillus 
megatarium 
Nanoparticles ranged 
from 30 to 60 nm 
Data not shown 
Reaction of copper nanoparticles of 100 nm 
with B. subtilis showed the highest 
susceptibility (Z = 0.0734 mL/µg) whereas the 
reaction of silver nanoparticles of 40 nm with 
E. coli showed the lowest one (Z = 0.0236 
mL/µg) 
Data not 
shown 
[130] 
B. megatarium,  
S. epidermidis, 
E. coli 
MRSA 
Average size of 1.36 ± 0.6 
nm 
CuCl2 as the precursor, D (+) 
glucose as the reducing agent, 
soluble starch as the NP 
stabilizing agent 
Cu1X and Cu10X kill B. megatarium, S. 
epidermidis, E. coli and MRSA 
Data not 
shown [131] 
E. coli 
S. aureus 
Spherical morphology 
and a narrow size 
distribution with 7 and 14 
nm 
Mechanochemical method using 
two different Cu-containing 
precursors (i.e., CuSO4·5H2O 
and CuCl2·2H2O) 
CuCl2·2H2O derived nanoparticles showed 
more antibacterial activity than CuSO4.5H2O 
derived nanoparticles 
E. coli  
MIC:3.75 
mg/mL 
S. aureus  
MIC: 2.50 
mg/mL 
[132] 
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Table 4. Antibacterial applications of Au-based nanoparticles, with respective minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) 
values. 
Nanoparticles 
Efficacy 
Physicochemical Characteristics of 
the Nanoparticles 
Production Method Therapeutic Efficacy (Tests 
Employed) 
MIB and MIC 
Values 
Reference 
P. aeruginosa 
Average size 18.32 nm Biological method (extract of A. comosus) Disc diffusion 
method 
MIC, MIB: 4 
µg/mL  
[148]  
S. aureus MIC: 3.92 
µg/mL 
E. coli Average size 150 nm Biological method (extract of M. piperita) 
Disc diffusion 
method 
MIB: 12–16 
µg/mL 
MIC: 4 µg/mL 
[149] 
K. pneumoniae Average size 77.13 and 38.86 (due 
to extraction method) 
Biological method (extract of G. elongate) Standard agar well diffusion 
method 
MIC: 3.3 
µg/mL 
[148] 
S. typhimurium Average size 25 to 35 nm Biological method (extract of S. 
brachiate) 
Disc diffusion 
method 
MIC, MIB: 8 
µg/mL 
[150] 
K. oxytoca 
Average size 18.7 to 93.7 nm Biological method (extract of S. 
marginatum) 
Agar well diffusion method 
Data not 
shown 
[46] 
E. faecalis Data not 
shown 
V. cholerae Data not 
shown 
S. paratyphii Data not 
shown 
V. parahaemolyticus Data not 
shown 
P. vulgaris Data not 
shown 
B. subtilis Average size 6 to 40 nm Chemical method [sodium borohydride 
(NaBH4) as a reducing agent+ 
Enzyme-linked 
immunosorbent assay (ELISA) 
MIC 7.56 
µg/mL 
[148] 
Nanomaterials 2020, 10, 292 28 of 43 
 
6. Zinc Oxide Nanoparticles (ZnONPs) 
Zinc is an essential mineral involved in the catalytic activity of numerous enzymes present in 
the organism and is widely distributed throughout the body tissue [151]. Zinc oxide (ZnO) is a 
multifunctional and biocompatible semiconductor material used in the preparation of many products 
including plastics, paints, ceramics, batteries and as an antibacterial [152]. In the pharmaceutical field 
it is recognized as one of the safest materials by the Food and Drug Administration (FDA) [50]. 
Nanosized ZnO presents great interest in the industrial sector because of its intrinsic properties as 
wide bandgap (3.37 eV), high-exciton binging energy (60 MeV), high electronic conductivity, 
nontoxicity and chemical stability [153]. ZnONPs exhibit significant optical properties that offer NPs 
the ability to be used as drug delivery system, as antitumor, antibacterial, antidiabetic and as 
theragnostic tool.  
6.1. Synthesis and Production Methods 
Among the most widely used techniques for synthetizing of ZnONPs are widely known the 
solution-based routes as chemical controlled precipitation, sol-gel method, solvothermal and 
hydrothermal method, method using an emulsion or microemulsion environment, among others 
[154]. ZnONPs are formed using as precursors mainly zinc nitrate (Zn(NO3)2), zinc sulphate (ZnSO4) 
and zinc acetate (Zn(CH3COO)2). Zinc oxide is organized spatially in two main forms: hexagonal 
wurtzite, the most stable form and therefore the most common and cubic zinc blende. In addition to 
this fixed form, after agglomeration ZnONPs may present different morphologies (e.g., nanorings, 
nanocombs or nanocages) which is determined by the synthetic route used [151]. The color change in 
the solution to yellow evidences the formation of this nanoparticles [155]. The simplified reactions of 
its synthesis are presented below [156]. 
Zn2+ 2OH−          Zn(OH)2 (8) 
Zn(OH)2 + 2OH−      Zn(OH)4−2 (9) 
Zn(OH)4−2             ZnO + 2H2O + 2OH− (10) 
Chemical strategies arise in the presence of noxious chemicals absorbed on the nanoparticles 
surface, producing adverse effects in medical application [154]. Biological or green synthesis consists 
on the use of non-toxic, environmentally friendly and safe reagents as microorganisms, enzymes and 
plants or plant extracts as reactive in the manufacture procedure of ZnONPs [154]. 
6.2. Pharmacokinetics 
According to the administration route, the bioavailability of ZnONPs differs. In the case of 
intravenous injection, nanoparticles are readily available in the bloodstream, while the bioavailability 
is much lower after oral dose. This phenomenon is explained by a limited absorption at 
gastrointestinal tract level, followed by a first-pass hepatic effect [157]. 
The ZnONPs distribution is influenced by the route of administration and the intrinsic 
physicochemical properties. ZnONPs have a wide distribution to organs such as the heart, spleen, 
liver, kidneys and lungs, accumulating specially in liver and kidneys, their main metabolic and/or 
excretion sites [158]. 
Despite being eliminated mainly by biliary clearance and faecal excretion, some smaller ZnONPs 
follow a minor route based on a renal excretion [157]. 
6.3. Antibacterial Properties 
ZnONPs possess antimicrobial activity against Gram-positive (S. aureus, S. epidermis, B. subtilis, 
B. cereus, L. monocytogenes, E. faecium) and Gram-negative (P. aeruginosa, E. coli, K. pneumoniae, 
Salmonella sp.) bacteria [50]. 
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Moreover, Singh et al. compared antimicrobial and antifungal potential of zinc oxide 
nanoparticles. Pathogenic microorganisms selected included different bacteria, Escherichia coli 
(MTCC 443), Staphylococcus aureus (MTCC 3160), Bacillus subtilis (MTCC 441) and two fungi, 
Aspergillus niger (MTCC 281), and Candida albicans (MTCC 227). They show a 50% efficacy when 
nanoparticles are used instead of particles [159]. Antimicrobial tests carried out with different 
bacterial strains show than the minim inhibitory concentration (MIC) values are 50–85% lower in 
Gram-positive than Gram-negative bacteria. 
The difference in antibacterial activity of ZnONPs towards Gram-positive and Gram-negative 
bacteria could be clarified due to the interaction with the cell wall. In Gram-negative bacteria, the 
structure of lipopolysaccharide opposes the attachment of ZnO and restrains the ions passing across 
the outer membrane [160]. 
The toxicity induced by antimicrobial drugs is due to modifications in the membrane potential 
through the blockage of K+ ion channel present in the bacteria cell membrane. ZnONPs in aqueous 
medium are dissolved with consequent release of Zn2+. Zn2+ ions, that are attracted to the bacterial 
surface causing this phenomenon. These changes increased permeability of the membranes leading 
to destabilization. Moreover, ROS production by nanoparticles contributes to this result [157]. 
Due to their charge, Zn2+ ions can easily penetrate the bacterial cell wall and interact with 
different molecules—such as lipids, proteins, and nucleic acids—disrupting important metabolic 
pathways. In presence of acidic pH nanoparticles shows a higher antimicrobial activity due to the 
increase in the dissolution and release of Zn2+ (as described below) [157]. 
ZnO + 2NaOH   basic medium   Na2ZnO2 + H2O (11) 
ZnO + 2NaOH    acidic medium    ZnCl2 + H2O (12) 
ZnCl2    aqueous medium     Zn+2 + 2Cl− (13) 
Several authors have used ZnONPs as antimicrobial agents either as ZnO alone or in 
combination with drugs [161]. Recently, ZnONPs have been developed using a plant extract (Punica 
granatum) and obtaining spherical and hexagonal shapes of 32.98 nm diameter with antibacterial 
activity against E. coli and E. faecalis [162]. Moreover, Jayabalan et al. in their last work have 
demonstrated that the ZnONPs synthetized using a biological method based on the use of 
Pseudomona putida, obtaining nanoparticles with a spherical shape and an average diameter of 44.5 
nm. This ZnOPNs presented antimicrobial activity against Pseudomonas otitidis, Pseudomonas 
oleovorans, Acinetobacter baumannii, Bacillus cereus, and Enterococcus faecalis using microtiter plate 
method and disk diffusion assay (Table 5) [163].  
6.4. Other Pharmaceutical Properties 
Recently ZnONPs have been found to have the potential to be used in cancer therapy since they 
exhibit tumoral cell selectivity showing enhanced in vitro cytotoxicity by generation of ROS. 
Furthermore, ZnONPs induce proinflammatory markers as interferon-c, IL-12 and tumor necrosis 
factor-α (TNF-α) in peripheral blood mononuclear cells [164]. Several studies demonstrated that 
ZnONPs cause genotoxic effects including DNA damage in neuronal and human epidermal cancer 
cells [156]. 
Different studies have assessed the effect of ZnONPs in antidiabetic activity. Bala et al. have 
observed a reduction of blood glucose levels when administered the ZnONPs in diabetes induced 
mice [165]. Other authors have shown that it results in a synergic effect when combined these 
nanoparticles with an antidiabetic drug as Vildagliptin in diabetic-induced rats [166].  
Due to the ZnONPs ability to absorb radiation, they are UVA and UVB reflectors approved to 
be used as a physical sunblock since they are completely photostable, non-allergenic, non-irritating 
and non-comedogenic. Zinc oxide blocks every UVA (320–400 nm) and UVB (280–320 nm) rays [167]. 
Therefore, ZnONPs are used in the preparation of sun creams in combination of TiO2, acting as a 
successful UV blocker [168]. Currently, large brands of dermocosmetic that manufacture sunscreens 
use this type of nanoparticles mainly as physical filters in sunscreens.
Nanomaterials 2020, 10, 292 30 of 43 
 
Table 5. Antibacterial applications of zinc oxide nanoparticles, with respective mminimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) 
values. 
Organism 
and Specie against 
the Nanoparticles are 
Effective 
Physicochemical 
Characteristics of the 
Nanoparticles 
Production Method Therapeutic Efficacy Assessment MIB and MIC Values Reference 
Escherichia coli 
 
Enterococcus faecalis  
Spherical and 
hexagonal-shaped 
UV–Vis absorption 32.98 
nm (600 °C) 
UV–Vis absorption 81.84 
nm (700 °C) 
Green method 
Biosynthesis of ZnO-NPs 
using Punica granatum fruit 
peels extract 
Antimicrobial susceptibility test shows effective 
antibacterial activities against two strains of 
bacteria 
Cell proliferation assay shows selective toxicity 
towards 
colon cancer cells (HCT116) and proved non-
toxic to normal cell 
(CCD112)  
MIC E. coli – 
64.53 µg/mL  
 
MIC E. faecalis 
– 22.09 µg/mL 
[162] 
Pseudomonas otitidis 
Pseudomonas 
oleovorans 
Acinetobacter 
baumannii 
Bacillus cereus 
Enterococcus faecalis 
Spherical shape 
Average size 25–45 nm 
Green method  
Biogenic synthesis of ZnO 
NPs using 
Pseudomonas putida broth 
culture 
Antibacterial microsomal triglyceride transfer 
protein assay shows effective antibacterial 
activities against all strains of bacteria 
MIC 10 µg/mL 
in all bacteria 
[163] 
Staphylococcus aureus 
Hexagonal shape 
UV–Vis absorption 25.57 
nm  
ζ-potential −20.9 mV 
Green method 
Biosynthesis of ZnO-NPs 
using Cinnamomum 
Tamala leaf extract 
Broth dilution assay, protein leakage analysis, 
membrane stability analysis, and growth curve 
analysis show a time and concentration 
dependent reduction in bacterial growth 
MIC 40 µg/mL [169] 
Escherichia coli  
Listeria monocytogenes 
Uniform rod-shape 
Average size 20-30 nm 
diameter, 100–150 nm 
length  
Green method 
Synthesis using KOH as a 
hydrolysing agent 
The viable colony count method shows 
effective antibacterial activities against both 
strains of bacteria 
Data not 
shown [170] 
Escherichia coli   
Spherical shape 
Average size 60–80 nm Green method 
Growth kinetic assay demonstrated 
bacteriostatic effect  MIC 20 µg/mL [157],[171] 
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Phyto-assisted synthesis of 
ZnO-NPs using Cassia 
alata fresh leaves 
Bacillus cereus 
Bacillus subtilis 
Escherichia coli 
Klebsiella pneumoniae 
Staphylococcus aureus 
Serratia marcescens 
Needle like shape 
Average size 90–110 nm 
Green method 
Phyto-assisted synthesis of 
ZnO-NPs using Berberis 
aristata leaf extract 
Antibacterial activity assay shows effective 
antibacterial activities against all strains of 
bacteria and MIC was determinate. The 
maximum activity was found against Bacillus 
subtilis 
MIC 
B. cereus – 128 
µg/mL  
B. subtilis – 64 
µg/mL 
E. coli - 256 
µg/mL 
K. pneumoniae 
– 256 µg/mL 
S. aureus - 128 
µg/mL 
S. marcescens 
64 µg/mL 
[172] 
Staphylococcus aureus 
Escherichia coli 
Salmonella paratyphi 
Spherical shape 
Average size 20–50 nm 
Green method 
Biosynthesis of ZnO-NPs 
using aqueous 
Tabermaemontana divaricata 
leaf extract 
Antibacterial activity assay shows effective 
antibacterial activities against all strains of 
bacteria 
Data not 
shown 
[173] 
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6.5. Toxicity Assessments 
Regardless of the advantages and potential applicability of nanoparticles against bacteria, some 
doubts remain about their potential toxicity and risk to human health. 
Even though metal-based nanoparticles have been shown to be more toxic to bacteria than to 
eukaryotic cells, their extensive distribution and accumulation over time predicts that the same 
mechanisms responsible for their efficacy against bacteria may also be responsible for potential 
adverse effects [174]. 
Production of ROS by nanoparticles and generated oxidative stress have been associated with 
inflammatory processes responsible for many disorders, such as pulmonary diseases and liver 
degeneration [175]. 
6.5.1. Pulmonary Toxicity 
In the lungs, metal-based nanoparticles are involved in acute and subacute inflammatory 
processes with release of pro-inflammatory cytokines [176]. These inflammatory processes may be 
reversible depending on dose and exposure duration, but in some serious cases, they have been 
associated with the development of pulmonary bronchitis, emphysema, and moderate fibrosis [177]. 
Chung et al. detected a mild to moderate inflammation with infiltration of neutrophils, 
eosinophils, monocytes/macrophages, and some lymphocytes in the bronchial and exudates in the 
alveolar space after instillation with silver nanowires in Sprague-Dawley rat lungs [178]. Gosens et 
al. and Jacobsen et al. also proved the occurrence of the same effects after administration of CuONPs 
and ZnONPs, respectively [179]. Other authors observed dose-dependent lung inflammation with 
alveolitis, bronchiolitis, vacuolation of the respiratory epithelium and emphysema after short-term 
inhalation exposure to CuONPs [179] while Jacobsen et al. noticed a very strong inflammatory 
response in the lungs after exposure to ZnONPs [180]. 
6.5.2. Hepatotoxicity 
In the liver, high accumulation of metal-based nanoparticles has been associated with elevation 
of liver biomarkers (AST, ALT, GGT), hepatic inflammation and pro-inflammatory activation of 
Kupffer cells in the liver. At the same time inhibition of several cytochrome P450 enzymes (CYP1A, 
CYP2C, CYP2D, CYP2E1, and CYP3A) have also been reported [181]. Similarly, Almansour et al. also 
proved that ZnONPs have potential oxidative stress in hepatic tissues resulting in Kupffer cells 
hyperplasia, inflammatory cells infiltration, hepatocytes apoptosis and necrosis after performing a 
study where he evaluated ZnONPs hepatotoxicity in male Wistar albino rats [182]. 
6.5.3. Nephrotoxicity 
It has been observed an increase in blood urea nitrogen levels and serum creatinine levels in 
animals treated with CuONPs and ZnONPs respectively, with evidence of tubular epithelial cell 
necrosis observed in the second case. These results corroborate the hypothesis of renal dysfunction 
potentially induced by oxidative stress [183]. 
Although Ibrahim et al. reported some pathological changes in the kidney after exposure to 
AuNPs during work, such as alterations in glomeruli, dilated tubules, oedema exudate, mild necrosis, 
and infiltration of inflammatory cells; these pathological changes were considered minimal and 
insignificant in the kidneys, regardless of the size of the AuNPs [184]. 
6.5.4. Neurotoxicity 
It has been proven that nanoparticles may cause some degree of damage to the blood–brain 
barrier leading to increased permeability and facilitating its penetration into the central nervous 
system (CNS). [185]. Similarly, AgNP and ZnONP toxicity was also associated with the accumulation 
of nanoparticles in the brain, responsible for some degree of neuroinflammation and 
neurodegeneration caused by ROS induced CNS injury [186]. 
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6.6. Other Side Effects 
ZnONPs intake has been also associated with anaemia resulting from toxicity against 
erythrocytes which resulted in hemolysis and decreased count of red blood cells. Besides oxidative 
stress which is seen for all metal-based nanoparticles and to which erythrocytes are quite sensitive, 
ZnONPs show an additional mechanism of toxicity to red blood cells. A high intake of zinc causes a 
deficit of copper and iron. In rodents, iron deficiency is the most frequently reported cause of anemia 
in the literature [187]. 
After oral administration, gastrointestinal side effects have also been frequently reported. The 
most commonly reported gastrointestinal reactions include nausea, vomiting, diarrhea, and 
gastrointestinal hemorrhaging. These side effects are produced by the diffusion and passage of 
nanoparticles into the intestinal enterocyte and epithelium reaching the systemic circulation. In 
addition, the strong acid media (pH~2) favors, metallic and metal oxide nanoparticles dissolution 
into metal ions. They penetrate cells via ion channels and biological pumps and when they exceed 
tolerable range, toxic effects occur [188]. It is due to an inflammatory cell response induced by an 
intracellular production of ROS. These high ROS levels produce damage in the DNA of the cells and 
may result in cell death [189]. It was found that people without underlying health problems were less 
likely to develop adverse reactions when compared to people with comorbidities, such as obesity or 
high levels of cholesterol in the blood. Due to the extended list of adverse reactions, during the 
administration of metal-based nanoparticles, it may be relevant to access the patient’s health profile 
[190]. 
7. Comparative Overview 
Although the different types of metal nanoparticles here discussed have a wide range of 
applications in several industries, with the discovery of their antimicrobial activity, AgNPs have 
taken a leading role since 2016 when they were marketed the first time. Their market is expected to 
exceed USD 3 billion in 2024 [191]. 
Although AgNPs have shown to be highly reactive and to have high antibacterial activity 
compared to others (e.g., CuONPs, AuNPs, and ZnONPs), their accumulation in the body and 
potential toxicity to the various organs may limit their use. This is the main reason why other metal-
based nanoparticles are being studied. According to Bondarenko et al., MIC values for bacteria for 
Ag, CuO, and ZnONPs are 7.1, 200, and 500 mg/L [192]. Regarding AgNPs, acute oral exposure to 
AgNP at doses relevant to potential human exposure is associated with predominantly faecal 
elimination and not with increased toxicity [193]. On the other hand, high concentrations of AuNPs 
administered orally or intraperitoneally in rats, induced a decrease in body weight, red blood cells, 
and hematocrit. Moreover, it has been also reported that AuNPs orally administered in rodents cause 
significant decreases in body weight, spleen index, and red blood cells [194]. Regarding ZnONPs, 
during prolonged oral administrations in mice, they can cause cardiac damage [195]. CuO and 
ZnONPs, for example, are composed of copper and zinc, two essential microelements, which are less 
toxic to mammalian cells because these have mechanisms of homeostasis that regulate the 
concentrations of these metals inside the cells. However, in fish exposed to 0.25 mg/L copper, copper 
sulfate, and copper oxide nanoparticles dissolved copper damaged the fish liver and kidney more 
severely than copper nanoparticles [196]. 
AuNPs were originally investigated for their applicability as biosensors, bio-imaging, and drug 
delivery systems and not for their antibacterial activity. However, with the discovery of unfavorable 
toxicity profiles of other nanoparticles AuNPs antibacterial activity was also investigated since they 
are relatively inert and biocompatible [126]. Despite these advantages, AuNPs have considerably 
lower antibacterial activity in comparison with AgNPs. 
8. Conclusions 
Metal-based nanoparticles are being extensively used in biomedical sciences and in engineering. 
Their market has heavily increased over the last few years and it is not expected to decrease. We have 
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revised the main features of AgNPs, CuONPs, AuNPs, and ZnONPs, commonly being exploited for 
medical and pharmaceutical applications (e.g., as antibacterial, antifungal, antiviral, antiamebial, 
anti-cancer, anti-angiogenic, anti-inflammatory agents). Due to their well-described antimicrobial 
activity against Gram-positive and Gram-negative bacteria, these particles have been proposed as 
alternative over traditional antibiotics to overcome bacteria resistance. Nanoparticles make use of 
mechanisms of action that differ from the classical treatments, with the advantage of being active 
against bacteria that have already developed antibiotic resistance, but also by targeting multiple 
biomolecules which compromises the development of resistant strains. Any potential risk of 
toxicological events in humans when using metal nanoparticles is attributed to their physicochemical 
properties, dosage, and administration route, which govern their pharmacokinetics and 
pharmacodynamics. As these particles may have a narrow therapeutic window, an exhaustive 
physicochemical characterization in the early stages of pharmaceutical development is 
recommended. Besides, the understanding of their in vivo behavior during preclinical and clinical 
trials is a vital source of information for the success of pharmaceutical development, so that failures 
in late phases of research and development are avoided. 
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